Coronary artery disease (CAD), also known as coronary heart disease or ischemic heart disease, is an atherosclerotic disease characterized by the formation of plaques on the inner walls of coronary arteries, subsequently blocking blood supply to the heart.1 CAD manifestations include stable angina, unstable angina, myocardial infarction and sudden cardiac death.2 CAD is estimated to be afflicting 126 million individuals (1,655 per 100,000) worldwide and is the most common cause of heart disease deaths in Hong Kong.3,4 Since plaque progression is associated with significantly increased cardiovascular (CV) risks in CAD patients, enormous efforts have been made to achieve plaque stabilization and regression among these patients so as to reduce the occurrence of future CV events.5,6 In an interview with Omnihealth Practice, Dr. Fung, Chi-Yan Raymond discussed the added value of evolocumab for plaque stabilization and regression in statin-treated CAD patients, as well as possible strategies to reduce CV risks in CAD patients.
